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The production of layered double hydroxide(LDH) nanocomposite as an alternative drug delivery system against
various ailments is on the increase. Their toxicity potential is usually dose and time dependent with particle sizes,
shapes and surface charge playing some role both in the in vitro and in vivo studies. The reticular endothelial
system of especially the liver and spleen were shown to sequestrate most of these nanocomposite, especially those
with sizes greater than 50 nm. The intracellular drug delivery by these particles is mainly via endocytotic pathways
aided by the surface charges in most cases. However, structural modification of these nanocomposite via coating
using different types of material may lower the toxicity where present. More importantly, the coating may serve as
targeting ligand hence, directing drug distribution and leading to proper drug delivery to specific area of need; it
equally decreases the unwanted nanocomposite accumulation in especially the liver and spleen. These
nanocomposite have the advantage of wider bio-distribution irrespective of route of administration, excellent
targeted delivery potential with ease of synthetic modification including coating.
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Layered double hydroxide (LDH) nanocomposite is a class
of inorganic material with chemical composition repre-




[An-] x/n⋅mH2O] where M
2+ and M3+ are divalent and
trivalent metal cations respectively [1]. The unique struc-
ture of LDH consisting of an outer positively charged
metal hydroxide sheets and inner interlayer anions hy-
drated with water molecules aiding in its uptake and cellu-
lar penetration [1,2]. A controllable anion exchange that is
pH dependent is possible due to the fascinating structure
of LDH, which is also the basis of controlled-release prop-
erties of this carrier, making it a valuable choice for bio-
logical and pharmaceutical applications [3]. The synthesis
and study of LDH have been on-going for decades [4]. In
recent years, the synthetic production is on the increase
due to their potential in electronics, drug/gene delivery,* Correspondence: sharida@upm.edu.my
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publicdomain/zero/1.0/) avaccine delivery system, diagnostic imaging among others
[5]. In the field of biomedical application, different types
of LDH were exploited for drug delivery, although they
are still in the preliminary stage, but the results are prom-
ising and likely to join other delivery systems, that have
reached an advanced level of clinical trials and use [6].
Some particularly interesting application of nanoparticles
in general and LDH in particular includes alternative drug
delivery system. This, resulted from their; local sustained
release; high intrinsic pharmacological activity compared
with conventional drugs. They also have improved the
delivery of poorly water-soluble drugs, targeted delivery of
drugs in a cell- or tissue-specific manner, transcytosis of
drugs across tight epithelial and endothelial barriers (blood
brain barrier inclusive), and delivery of large macromol-
ecule drugs to intracellular sites of action [7-10]. Thus, the
synthesis of LDH for drug delivery covered wide group of
drugs, including but not limited to CNS diseases [7], can-
cers [8], anti-inflammatory and antibiotics [9] and imaging
agents [10].
Below is a table (Table 1) that summarizes different type
of layered double hydroxide nanocomposite synthesizede Chemistry Central Ltd. This is an Open Access article distributed under the
mons Attribution License (http://creativecommons.org/licenses/by/4.0), which
distribution, and reproduction in any medium, provided the original work is
eative Commons Public Domain Dedication waiver (http://creativecommons.org/
pplies to the data made available in this article, unless otherwise stated.
Table 1 Layered hydroxide nanocomposite toxicity and bio-distribution studies
Nanocomposite type Method of synthesis Size (nm) Concentration (μg/ml) Assay (Test) Cell type Refr ce Remark
1. Mg–Al–LDH Co-precipitation/ion
exchange
50-100 40 MTT Human kidney (N) [4] Contain folic acid and not toxic, more than
80% of cell viable after 3days.
2. Zn–Al–LDH Co-precipitation _ 150 MTT Mouse fibroblast (C) [7] Higher fibroblast viability with LDH-levodopa
treatment than pure levodopa, LDH alone no
significant effect on fibroblast
3. ZLH Direct method _ 20 MTT Human liver cell
(HepG2) (C)
[8] Hippuric acid (HA) intercalated ZLH showed
better synergy than pure HA and tamoxefen
on cancer cells.
4. Mg–Al–LDH Co-precipitation 150-200 100 MTT Colon cell(C) [10] LDH coated with chitosan also not toxic
at this dose on this cells
5. Mg–Al–LDH Ion exchange >300 Animal single dose Whole animal [13] Contain captopril and not toxic to the
animal exposed.
6. Mg–Al–LDH Co-precipitation 80-90 20 MTT Human cervical cancer (C) [16] Potentiate the effect of paclitaxel
7. Mg–Al–LDH Co-precipitation 129-149 100 MTT/Trypan blue Cortical neuron(N) [17] DNA loaded LDH less toxic than pristine
LDH at higher dose
8. Mg–Al–LDH Co-precipitation _ 1000 MTT Human osteosarcoma (C) [18] 5-fluorouraci loaded LDH show better
effect than free drugs
9. Mg–Al–LDH Co-precipitation 50,100,200,350 MTT Fibroblast(N) and lung(c) [20] Potentiate the effect of anti-cancer and
milder on normal cells
10. Mg–Al–LDH/Zn-Al-LDH Co-precipitation _ 80mg/kg of
ketoprofen
Magnifying lens Mucosal surface [21] Ketoprofen induced gastritis was reduced
with LDH intercalation
11. Mg–Al–LDH Co-precipitation _ 5-2000mg/kg Blood chemistry Balb/c mice [26] No significant changes to clinical and
biochemical parameters and no evidence
of particle retention in tissues.
12. Zn-Al-LDH Co-precipitation/ion
exchange
_ 1.2 MTT Chang liver cells (N) [29] Lower concentration used and no effect on
viability from either the carrier or loaded LDH
13. ZLH Direct method _ 1000 Trypan blue Chang liver cells (N) [30] No Significant cell viability decrease below
125μg/ml with good anti histamine release
from the intercalated cetirizine.
14. Zn-Al-LDH Direct method 150 800 MTT, GSH, ROS,
NO, comet assay,
Cervical cell (Hela) (C) [32] Only dose above 400ug/ml causes DNA
damages, hence biocompatibility possible
since it has no toxic
effect at lower doses base these assays.
15. Zn–Al–LDH Co-precipitation/ion
exchange
_ 50 MTT Mouse fibroblast
and human lung
fibroblast cells
[33] The toxic effect of Para-amino salicylic acid
on the two cells was decrease after
intercalation into this LDH





[34] More than 50% of cells viable at 500μg/ml.














Table 1 Layered hydroxide nanocomposite toxicity and bio-distribution studies (Continued)
17. Mg–Al–LDH Co-precipitation/ion
exchange
57-63 40 MTT Human gastric epithelial cell
(GES-1) gastric cancer cell
(MKN45 and SGC-7901)
[36] Etoposide harmful effect on normal cell
significantly reduced and its anticancer effect
enhanced after intercalation into LDH.
18. Mg–Al–LDH Co-precipitation _ 50 MTT Breast (MCF-7) (C),cervical
(HeLa) (C), and fibroblast
(3T3) (N)
[37] Not toxic to all the three cell line, but
enhanced the anti-cancer effect of
protocatechuic acid.
19. Mg–Al–LDH Co-precipitation 20 50 MTT lung fibroblast cell (N) [38] No toxic effect against the tested cells
and bacteria. Activity of the intercalated
antibiotics similar to the naked one
The table summarises some of the layered hydroxide nanocomposite activity in relation to toxicity and distribution over the last few years. The majority of whom were synthesis by either co-precipitation or ion exchange
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nanometre, type of test conducted and their outcome
in relation to toxicity or drug enhancement especially
against cancers.
Several methods have been used for LDH synthesis,
among which are the co-precipitation, ion exchange,
urea hydrolysis, structural reconstruction and sol-gel
methods [1]. Differences in method of synthesis affect
not only the crystalline nature of the particles, but also
the loading capacity and quantity produced [4]. Folic
acid intercalated into a magnesium aluminium hybrid
via Co precipitation and ion-exchange method demon-
strated 19 and 17% loading of the drug respectively [4].
Manoeuvres like sonication, hydrothermal treatment and
microwave irridation usage during aging demonstrated
changes to the morphology of particles [1]. However, in
a drug delivery system study, most researchers demon-
strated good and successful intercalation of different drugs
into either zinc- aluminium or magnesium aluminium
based LDH using Co precipitation and or ion-exchange
methods [11,12]. The emergence of Nanomedicine is of
outmost importance in the health system, more so in the
area of drug delivery. Over the last few decades, several of
such delivery systems have been synthesized and tested,
few of which have made it to commercial stage [13]. Lay-
ered double hydroxide in particular is regarded as one of
those with the least toxicity among the inorganic types
[14]. They are relatively easy to synthesize in the labora-
tory, with different controllable sizes, shapes and other re-
lated features [1,2,4]. No single parameter has yet been
identified as the one being responsible for most nanoparti-
cles toxicity, LDH inclusive [15,16], but many physico-
chemical parameters have been proposed to be critical
determinants in nanomaterial toxicity, among which
are; crystalline structure, surface area, oxidation status,
size and chemical composition of the nanoparticle
[15,16]. This review aims at discussing LDH in delivery
of drugs with emphasis on wider distribution potential,
organized cellular uptake mechanism, drug enhance-
ment activity especially, anti-cancers and their charac-
teristics decrease toxicity potential in drug delivery
when compared to pure drugs.
Review
Bio-distribution and cellular uptake
Decade’s back, passive diffusion was shown to be the main
mechanism in drug transport across biological barriers, it
is a key determinant in pharmacokinetics [17]. Later stud-
ies showed carrier mediated process in drug transport
across the biological membrane also played major roles,
adding to the existing passive mechanism [17]. The two
processes are vital in drug transport to areas of interest
irrespective of admission route. In the case of LDH, the
positively charged outer sheet of the delivery system isattracted by a negatively charged cell membrane, enables a
facile penetration of LDH into cells [5]. A study was done
previously to show the impact of surface charge on LDH
and the mechanism of its cellular uptake [18]. There, a
fluorescence and transmission electron microscope (TEM)
were applied, to demonstrate the endocytotic cell entrance
of paclitaxel-LDH nanoparticles bounded with an anti-
body called fluorescein isothiocyanate (FITC) into cervical
cancer cells (Hela) [18]. The positive charge outer layer of
LDH whose zeta potential is 20.3 mV aided in the uptake
and cell penetration [18]. In order to identify the specific
endocytotic pathway for LDH entrance into the cells, the
researchers blocked the clathrin and caveolin-mediated
(endocythotic receptors) pathways using chlorpromazine
and nystatin (inhibitors) respectively on a neuronal cell.
With a chlorpromazine blockage, there was no vesicle for-
mation following treatment with LDH, but no effect clearly
shown with nystatin treatment [19,20]. An anti-cancer
loaded LDH was shown to enter a cervical cancer cell via
the above mentioned clathrin-mediated endocytosis also
[21]. The study further excluded caveolae-mediated endo-
cytosis of the methotrexate loaded LDH into the cancer
cells [21]. Some accessory cellular protein studies were used
to prove the inclusion of the former and exclusion of the
latter mechanism [21]. Hence, LDH cellular uptake and
penetration is via endocytosis and mainly through clathrin-
mediated pathways.
Further influence in LDH particle uptake is the par-
ticle size and shapes, with sizes between 50-200 nm
showing concentration dependent uptake, while sizes
350 nm and above not concentration dependent [5].
Both hexagonal and rod shape LDH nanocomposite en-
tered the cells through the same endocytotic pathway;
however the hexagonal shaped particle was found to be
distributed within the nucleus of the cells [5]. The pretti-
ness of such findings is to do with possible usage of
LDH in gene delivery to the nucleus in gene therapy and
other related gene application. These results suggested
further, the promising drug delivery potential of LDH
at the cellular level without necessary damaging cell
structure. Further research on synthesis and applications
should focus on the size and shape specific LDH pro-
duction in order to improve their actual medical applica-
tion especially in areas of drug delivery.
The distribution of layered double hydroxide nanocom-
posite is not much different from the rest of nanoparticles,
reticular endothelial system (RES) takes larger amount, es-
pecially the liver, kidney, spleen and lungs [5]. The sizes of
the particle play significant role in determining the particle
distribution [5]. Particles less than 5 nm are easily re-
moved by the renal clearance; sizes more than 100 nm, are
mostly sequestrated by the RES of the liver, lungs, kidney
and spleen [5]. Intra-peritoneal administration of LDH
to mice for five days with sizes 100 – 200 nm showed a
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but not brain and/or heart [22]. Both zinc and aluminium
based LDH revealed good plasma distribution of non-
steroidal anti-inflammatory drug (NSAID) after oral inges-
tion and the analgesic effectiveness is almost similar to its
counterpart (pure NSAID), added with advantage of in-
crease gastric tolerability [23]. LDH containing antibiotics
as a local drug delivery system also showed promising re-
sult [24]. This was made possible due to likelihood of sus-
tained release and low toxicity properties of this noble
carrier leading to a good drug delivery to infected middle
ear in the presence of prosthesis. More recently, an in vivo
study conducted by a group of scientist showed the distri-
bution of LDH to liver, lung and spleen following an intra-
venous tail vein injection [10]. This same LDH carrier
showed preference to the lung when coated with Chitosan.
Further increase Chitosan concentration (higher concen-
tration) leads to accumulation in liver and avoided the
lung [10]. This preferential in vivo bio-distribution of LDH
following modification of coating substance opened a high
potential for developing organ-specific drug-delivery sys-
tems using this noble carrier both in diagnosis and ther-
apy. In general, findings of wider distribution via different
routes of administration within the range of 50-250 nm
are further adding to the merits of LDH in drug delivery
potential. However, more needs to be done, especially, the
role of different coating material and active targeting in
delivering LDH to specific areas of interest.
Invasion of brain tissue by exogenous substances/path-
ogens (drugs and microorganism) are strongly prevented
by the blood–brain barrier (BBB) [24]. The BBB serves
as a gate in preventing dangerous substances from enter-
ing the central nervous system (CNS), however, in doing
so other important substances, including drugs for treat-
ing CNS pathologies like Parkinson’s disease, Alzheimer,
infections and tumors are equally prevented [24,25].
Amidst these difficulties some inorganic nanoparticles of
iron oxide (ION) were able to reach the brain in signifi-
cant concentrations in experimental animals [26]. The
same type of nanoparticle (ION) showed over 80% uptake
of Amyloid beta (Aβ) in the presence of intact and
un-inflamed BBB in rats [27]. LDH nanocomposite of
magnesium aluminium had equally exhibited good
plasma distribution after oral ingestion; it was distributed
to most of the body organs, including brain even though
not statistically different from control tissue samples [28].
The particle size was found to be around 100 nm, and
the size is likely a part that makes it possible in achieving
wider distribution of most organs, including the brain
without being sequestrated by the RES [5].
Drug delivery to the brain is another emerging area in
Nanomedicine [27-29]. Several surfactants have been con-
sidered in coating nanoparticle for drug delivery to the
brain [29]. Nevertheless, Tween-80 coated nanoparticlesenhanced transport to brain than most surfactant used
[29]. Nanoparticles from copper (Cu), aluminium (Al)
and silver (Ag) with size range 50 to 60 nm suspended
in Tween-80 and administered parentally to experimen-
tal animal showed good brain permeation [30]. These
and other related findings can be considered in future
studies using LDH for drug delivery to the brain. The
brain delivery of different types of the nanoparticles
using Tween-80 coating is considered by some scientist
to be a ‘gold standard’ [29].Decrease toxicity and drug activity enhancement
Layered double hydroxide nanocomposite is now emer-
ging as potential new drug delivery system due to its low
toxicity and higher biocompatibility [18,31]. Some studies
have shown LDH to have the same or lower toxicity than
the corresponding pure drug it carries when tested on
normal cell lines [18,31]. Among which was the investiga-
tion of toxicity effects on Chang cells line, a normal liver
cell using trypan blue exclusion assay at various concen-
trations of zinc layered hydroxide (ZLH) and cetirizine
nanocomposite (CETN) [32]. CETN was found to have an
IC50 of 617 μg/mL, whereas the ZLH showed decrease
cytotoxicity with IC50 values of 670 μg/ml [32]. Perindopril
(PE), an anti-hypertensive agent showed a similar toxicity
effect on Chang cells compared to the corresponding
nanocomposite intercalated with PE [31]. The synthesis
was done by ion exchange and co-precipitation methods
[31]. The controlled, sustained and pH dependent release
property of LDH is making it biocompatible to most tis-
sues, cell and animals as a whole. As exciting as the tox-
icity evaluation results of most synthesized LDH are, their
application especially in drug delivery may be hindered by
lack of standardization of physicochemical parameters.
Among the critical considerations often missing are differ-
ences in sizes, surfaces charges and particle solubility,
which may lead to results misinterpretation especially
where comparism are made [33]. Nanoparticle exposure
to physiological fluids is another factor that may alter the
physicochemical properties leading to aggregate or ag-
glomerate formation and possible toxicity [33].
Nevertheless, the toxicity potential of many drugs were
significantly reduced after intercalation into either zinc or
magnesium nanocomposite. Drug efficacies including anti-
cancer potential were on the increase due to intercalation
in LDH nanocomposite, it was achieved alongside decreas-
ing unwanted anti-cancer side effect on normal cells
[18,34]. Most body organs, including the brain were access-
ible by LDH nanocomposite to deliver different types of
drug, achievable, especially with those particles whose sizes
are less than 250 nm [28]. Where specific area is the target
for particular drug delivery coating with various agents are
yielding amazing results [10].
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decreasing toxicity of parent compound, but also potenti-
ation of the desired effect, both in vitro and in vivo model
[18]. For example, Podophyllotoxin, is an agent with poor
water solubility and low bioavailability. These two negative
attributes have limited the success of Podophyllotoxin in
cancer treatment [18]. However, the anti-cancer activity
improved following intercalation onto this nanodelivery
system [18]. A time-dependent decrease in cervical cancer
cells (Hela) viability seen with exposure to 20 μg/ml of
paclitaxel (PPT) and its corresponding LDH nanocompos-
ite [18]. The LDH nanocomposite showed higher toxicity
(anticancer) effect than pure PPT [18]. This positive out-
come is due to better cell penetration of the new delivery
system, controlled and sustain release ability, increase sta-
bility of the active compound while inside the carrier.
LDH itself had no significant effect on the cancer cells
[18]. Other cancers where LDH’s resulted in an improved
anti-cancer activity are liver carcinoma cell line (HepG2)
[8]. This cancer was treated with tamoxifen alone and then
followed by a mixture of either hippuric acid or its nano-
composite (HAN). This was done to study the synergistic
effect of hippuric acid on liver cancer. The anti-cancer ef-
fect of tamoxifen increased about 2-fold when HepG2
cells were co-treated with HAN, whereas co-treatment
with pure hippuric acid did not increase the toxicity. This
shows improved anti-cancer activity as a result of synergy
and believed to be secondary to HAN permeation across
the cell membrane much more effectively than hippuric
acid alone [8]. MTT assay for cell viability also demon-
strated folic-acid–LDH complex to have better ability in
reducing cancer cell viability (p < 0.01) compared to folic
acid alone [34].
However, one thing in common to most LDH nanocom-
posite is, toxicity reduction compared to the pure drugs
intercalated in them. They also demonstrated a good anti-
cancer effect, even better than their corresponding pure
drugs. The readily controllable sizes, plus cell’s attraction
potentials of the LDH particle played role in cellular distri-
bution and uptake. They equally play vital roles in decreas-
ing toxicity and enhancing anti-cancer effects [35]. LDH
produces some tissues and cells friendlily by-products
(H20, Mg
2+, Al3+, Zn2+) under physiological conditions
(pH= 7.4 or less) [35]. This can cushion the acidification
tendencies in endosomes and lysosome of cells after the
nanocomposite uptake [35]. Thus, toxicity secondary to
high acidity will be reduced. Recently, we reported a sus-
tained, controlled, slow and pH dependent release of levo-
dopa from zinc aluminium nanocomposite that lasted
three-six days [7]. This slow releasing property of toxic
compounds from the interlayer sheet of LDH over time is
also a factor in suppressing drug toxicity.
Coating LDH with either polymers or surfactants have
a role to play on the toxicity, for example coating, zincaluminium LDH with Tween-80 further decrease its tox-
icity on neural cells [36]. Better dispersion due to coat-
ing may be responsible for the decrease toxicity noted
in that study, other “improved” physiochemical charac-
teristics in the coated nanomaterial are likely additional
reasons. Introduction of coating affect the characters of
nanoparticles like their surface charges, thermal stability,
crystalline morphology, cellular/tissue uptake, target and
ultimately toxicity profile in both tissue and animal expos-
ure studies [36,37]. A related metal oxide nanoparticle
(iron oxide) was coated with dextran and polymer poly-
ethylene glycol (PEG) in another study [36]. The coated
nanoparticle demonstrated decrease toxicity on the tested
cells compared to their corresponding uncoated nanopar-
ticles [38].
Microorganisms, including some bacteria are part of the
human system, called normal microbial flora, they usually
live in the mucous membranes and on the skin. They aid
in digestion, defend the body against harmful organisms
and help the immune system to mature, as such they are
considered medically beneficial [39]. Antibiotics or drug
delivery vehicle not capable of discriminating between the
beneficial and harmful microorganism may be dangerous
to human. Both Gram-positive (S. aureus) and Gram-
negative (E. coli) bacterial growth was not inhibited by
LDH usage as drug delivery agent at 250 μg/ml [40]. How-
ever, it successfully delivered anti-microbial silver nano-
particles that inhibit the growth of microbes [40]. This
inorganic nanohybrid material allows for an efficient deliv-
ery and interaction between silver nanoparticle (antibiotic)
and bacteria. It provides a flat form for possible better
drug delivery potential against pathogenic organism in a
sustain release fashion, without necessarily harming the
medically important organism in the body in future.
In vivo toxicity assessment of LDH was studied via a
modified Spearman-Karber statistic method called the
Trimmed Spearman Karber method, in which orally ad-
ministered captopril; LDH and LDH-captopril in Sprague-
Dawley rats were found to have LD50 of 6590 mg/kg,
7410 mg/kg and 7315 mg/kg respectively [41]. Both LDH
and LDH-captopril can be considered as relatively safe
since they have LD50 that lies between 5000-15,000 mg/kg
after oral dosing [41,42]. Some interesting recent ad-
vances in LDH usage as drug delivery include their use
as a delivery vehicle for anti-cancer in animal study
[2,43]. Methotrexate was intercalated into LDH and its
anti-cancer efficacy tested. The new delivery system
showed improved anti-cancer efficacy than pure metho-
trexate, better distribution potential and much lower
toxicity in the tested animals [43]. Some of the materials
used in LDH were classified medically as heavy metals
with possible consequences [13,44]. Zinc for example,
is a trace element needed by the body as cofactor for
some enzymatic reaction [45], while aluminium is used
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sure from any of these elements if taken in certain quan-
tity or taken in the presence of altered physiology, a good
example of which is in aluminium toxicity in chronic renal
disease patients or in the elderly [47-49]. Other elements
used in LDH synthesis poses different toxicity profiles
when their chemical structure changes from stable elem-
ent to free radical with oxidative potentials [50,51].
Conclusion
However, no standard size, shape or coating has been
set to assess the potential of this delivery vehicle in drug
delivery. Different researchers use different sizes, con-
centration, shapes, tissue, cells, animals and even meth-
odology in LDH assessment. Limited studies done to
assess this noble carrier for chronic toxicity. Thus diffi-
cult or even impossible to make a generalize conclusion
with regard to toxicity, distribution or drug enhance-
ment ability. Another aspect in need of extensive re-
search in the area of LDH nanocomposite for drug
delivery is the chemical transformation tendencies of
the parent metal in the body leading to free radical gen-
eration. LDH had proved to be promising in the area of
drug delivery, especially in the areas of cancer therapy
and MRI procedure. This nanodelivery system used ei-
ther an already existing drug/compound or new drug/
compound making them more efficient against various
disorders/diseases and or less toxic. Though, nanoparticles
size play a vital role in tissue distribution, but bio-
distribution potential of these noble carriers is significantly
influenced by surface coating. Some coating substances
act as a targeting agent with specific delivery potential
overriding the limitation caused by the particle size. The
toxicity profile of this delivery system can be acceptable,
as modification in size, shape, coating and functionaliza-
tion could be applied to manipulate the toxicity potential
where present. Generally, low toxicity and higher biocom-
patibility are virtues associated with LDH nanomaterial,
and it is now emerging as a potential new drug delivery
system. Cellular uptake of these carriers is usually coor-
dinated; receptor mediated and energy dependent pro-
cesses. As an alternative drug delivery vehicle layered
hydroxide nanocomposite of both zinc and magnesium
nitrate containing different chemotherapeutic agent
have positively enhanced anticancer activity of so many
cancer cells. They were also shown to decrease the
possible cytotoxic effect of the active agents on most
cell lines tested. On their own they had no anticancer
or antibiotic effects, but as delivery vehicles they are
yielding welcomed pharmacokinetics results. Wider
bio-distribution, decreases toxicity potential, enhanced
efficacy and targeted delivery will be the basis for contin-
ued usage of this nanocomposite in drug delivery system
in the future.Abbreviations
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